DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
AZD-5363 is an investigational drug.
There have been 32 clinical trials for AZD-5363. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2007.
The most common disease conditions in clinical trials are Lung Neoplasms, Small Cell Lung Carcinoma, and Adenocarcinoma. The leading clinical trial sponsors are AstraZeneca, Samsung Medical Center, and National Cancer Institute (NCI).
Recent Clinical Trials for AZD-5363
|Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects||AstraZeneca||Phase 2|
|Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects||Samsung Medical Center||Phase 2|
|Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer||National Cancer Institute (NCI)||Phase 2|